ENDOCAM/PECAM--A NOVEL VASCULAR CELL ADHESION MOLECULE
ENDOCAM/PECAM--A NOVEL VASCULAR CELL ADHESION MOLECULE
批准号:
2222803
负责人:
Steven Mark Albelda
金额:
$25.47万
依托单位国家:
美国
项目类别:
财政年份:
1991
资助国家:
美国
项目状态:
已结题
起止时间:
1991-04-01 至 2000-07-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PECAM-1 (CD31, endoCAM) is a member of the immunoglobulin superfamily
present on endothelial cells, leukocytes and platelets implicated in
angiogenesis, leukocyte transmigration, and leukocyte activation. The goal
of this proposal is to study the molecular basis of PECAM-1 function.
Preliminary data indicate that PECAM-I functions as an adhesion molecule
capable of mediating either heterophilic (PECAM-to unknown counter-
receptor) or homophilic (PECAM to PECAM) binding depending on the
structure of the cytoplasmic domain. Multiple alternatively spliced
isoforms of murine PECAM-1 have recently been identified and it appears
that presence of exon 14 within the cytoplasmic domain regulates ligand
specificity. To understand the molecular basis of this unique property and
to define the biological significance of alternatively spliced isoforms,
the following specific aims are proposed:
1. To precisely localize the regions of the cytoplasmic domain that
regulate the ability of PECAM-1 to bind in a homophilic or heterophilic
fashion and to define the mechanisms by which the cytoplasmic domain
regulates PECAM-1 function. This will be accomplished by construction and
characterization of PECAM-1 mutants with deletions and point mutations
based on the results of the naturally occurring isoforms that will allow
more precise localization of the "regulatory" region(s) with the
cytoplasmic domain, exploration of mechanisms by which the cytoplasmic
domain regulates PECAM-1 function, and use of chimeric constructs
containing various isoforms of the cytoplasmic domain of PECAM-1
transferred by adenoviral vectors to endothelial cells.
2. To define the regions of the extracellular domain responsible for
heterophilic or homophilic binding. This will be accomplished by mapping
the epitopes of a series of bioactive murine specific anti -PECAM-1
antibodies, evaluation of PECAM-1 constructs containing specific point
mutations in key regions identified by epitope mapping, and by testing the
ability of peptides that mimic the putative functional regions of the
extracellular domain to block homophilic and heterophilic PECAM-1-
mediated aggregation.
3. To determine the biological significance of the multiple PECAM-1
isoforms. This will be accomplished by evaluating peptides that mimic the
putative functional regions of the extracellular domain for their ability
to block human leukocyte transmigration through an endothelial cell
monolayer, testing the ability of peptides with defined in vitro functions
to block leukocyte transmigration into thioglycollate stimulated
peritoneum in an in vivo model of murine inflammation, and by
determination of in vitro and in vivo expression status of muPECAM-l
isoforms.
These studies will provide both a better understanding of the basic
mechanisms of cell-cell adhesion and of the structure/function
relationships of PECAM-I and may thus ultimately be of value in designing
therapies for inflammatory and malignant diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 2 - Preclinical studies: Overcoming tumor heterogeneity
-
批准号:10241978
-
项目类别:
-
资助金额:$51.54万
-
财政年份:2018
-
负责人:Steven Mark Albelda
-
依托单位:
Project 2 - Preclinical studies: Overcoming tumor heterogeneity
-
批准号:10006192
-
项目类别:
-
资助金额:$51.54万
-
财政年份:2018
-
负责人:Steven Mark Albelda
-
依托单位:
Core A - Administrative Core
-
批准号:10241980
-
项目类别:
-
资助金额:$12.94万
-
财政年份:2018
-
负责人:Steven Mark Albelda
-
依托单位:
Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers
-
批准号:10006051
-
项目类别:
-
资助金额:$210.15万
-
财政年份:2018
-
负责人:Steven Mark Albelda
-
依托单位:
Core A - Administrative Core
-
批准号:10006194
-
项目类别:
-
资助金额:$12.94万
-
财政年份:2018
-
负责人:Steven Mark Albelda
-
依托单位:
Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers
-
批准号:10241975
-
项目类别:
-
资助金额:$210.15万
-
财政年份:2018
-
负责人:Steven Mark Albelda
-
依托单位:
The role of TIM3 and CEACAM1 in anti-tumor function of human effector T cells
-
批准号:10215429
-
项目类别:
-
资助金额:$36.83万
-
财政年份:2017
-
负责人:Steven Mark Albelda
-
依托单位:
Use of Genetically Engineered T cells Targeting Tumor Stroma to Treat Lung Cancer
-
批准号:8578578
-
项目类别:
-
资助金额:$35.77万
-
财政年份:2013
-
负责人:Steven Mark Albelda
-
依托单位:
Use of Genetically Engineered T cells Targeting Tumor Stroma to Treat Lung Cancer
-
批准号:9101792
-
项目类别:
-
资助金额:$35.77万
-
财政年份:2013
-
负责人:Steven Mark Albelda
-
依托单位:
Use of Genetically Engineered T cells Targeting Tumor Stroma to Treat Lung Cancer
-
批准号:8739623
-
项目类别:
-
资助金额:$34.69万
-
财政年份:2013
-
负责人:Steven Mark Albelda
-
依托单位:
Genetic Influence on Incidence of Acute Lung Injury
-
批准号:7796690
-
项目类别:
-
资助金额:$35.67万
-
财政年份:2009
-
负责人:Steven Mark Albelda
-
依托单位:
Preclinical Studies
-
批准号:7133575
-
项目类别:
-
资助金额:$16.96万
-
财政年份:2006
-
负责人:Steven Mark Albelda
-
依托单位:
Administration
-
批准号:7133577
-
项目类别:
-
资助金额:$8.1万
-
财政年份:2006
-
负责人:Steven Mark Albelda
-
依托单位:
Genetic Influence on Incidence of Acute Lung Injury
-
批准号:6968184
-
项目类别:
-
资助金额:$42.06万
-
财政年份:2004
-
负责人:Steven Mark Albelda
-
依托单位:
Ovarian selective Adenoviral vector for gene therapy of ovarian cancer
-
批准号:6667427
-
项目类别:
-
资助金额:$16.54万
-
财政年份:2002
-
负责人:Steven Mark Albelda
-
依托单位:
The Role of PECAM in Models of Lung Injury
-
批准号:6534990
-
项目类别:
-
资助金额:$35.66万
-
财政年份:2002
-
负责人:Steven Mark Albelda
-
依托单位:
The Role of PECAM in Models of Lung Injury
-
批准号:6637863
-
项目类别:
-
资助金额:$35.66万
-
财政年份:2002
-
负责人:Steven Mark Albelda
-
依托单位:
The Role of PECAM in Models of Lung Injury
-
批准号:6784705
-
项目类别:
-
资助金额:$35.66万
-
财政年份:2002
-
负责人:Steven Mark Albelda
-
依托单位:
The Role of PECAM in Models of Lung Injury
-
批准号:6936583
-
项目类别:
-
资助金额:$35.66万
-
财政年份:2002
-
负责人:Steven Mark Albelda
-
依托单位:
Ovarian selective Adenoviral vector for gene therapy of ovarian cancer
-
批准号:6504974
-
项目类别:
-
资助金额:$16.54万
-
财政年份:2001
-
负责人:Steven Mark Albelda
-
依托单位:
海外基金